BR112023024906A2 - Compostos - Google Patents

Compostos

Info

Publication number
BR112023024906A2
BR112023024906A2 BR112023024906A BR112023024906A BR112023024906A2 BR 112023024906 A2 BR112023024906 A2 BR 112023024906A2 BR 112023024906 A BR112023024906 A BR 112023024906A BR 112023024906 A BR112023024906 A BR 112023024906A BR 112023024906 A2 BR112023024906 A2 BR 112023024906A2
Authority
BR
Brazil
Prior art keywords
compounds
proteins
treatment
relates
inhibiting
Prior art date
Application number
BR112023024906A
Other languages
English (en)
Portuguese (pt)
Inventor
D Jones Clifford
Inder Bhamra
Original Assignee
Redx Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2107637.7A external-priority patent/GB202107637D0/en
Application filed by Redx Pharma Plc filed Critical Redx Pharma Plc
Publication of BR112023024906A2 publication Critical patent/BR112023024906A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112023024906A 2021-05-28 2022-05-27 Compostos BR112023024906A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2107637.7A GB202107637D0 (en) 2021-05-28 2021-05-28 Compounds
GB202118635 2021-12-21
PCT/GB2022/051367 WO2022248885A2 (en) 2021-05-28 2022-05-27 Compounds

Publications (1)

Publication Number Publication Date
BR112023024906A2 true BR112023024906A2 (pt) 2024-02-15

Family

ID=82019773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024906A BR112023024906A2 (pt) 2021-05-28 2022-05-27 Compostos

Country Status (10)

Country Link
US (1) US20240279241A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347589A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024519170A (cg-RX-API-DMAC7.html)
KR (1) KR20240013776A (cg-RX-API-DMAC7.html)
AU (1) AU2022279653A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024906A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216294A1 (cg-RX-API-DMAC7.html)
IL (1) IL308438A (cg-RX-API-DMAC7.html)
MX (1) MX2023014138A (cg-RX-API-DMAC7.html)
WO (1) WO2022248885A2 (cg-RX-API-DMAC7.html)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
AU2022281749A1 (en) * 2021-05-24 2023-11-30 280 Bio, Inc. Nitrogen-containing heterocyclic compound, method for preparing same and use of same
WO2023018812A1 (en) * 2021-08-10 2023-02-16 Amgen Inc. Heterocyclic compounds and methods of use
US20240417412A1 (en) * 2021-08-10 2024-12-19 Amgen Inc. Heterocyclic compounds and methods of use
JP2024532735A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
WO2023020519A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. 1, 4-oxazepane derivatives and uses thereof
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
KR20240114793A (ko) 2021-11-05 2024-07-24 프론티어 메디슨즈 코포레이션 Kras g12c 억제제
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
WO2023107592A1 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Pyridopyrimidines and methods of their use
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
JP2025510656A (ja) * 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
CN116969977B (zh) * 2022-07-13 2026-05-01 重庆华森英诺生物科技有限公司 Pan-kras抑制剂
TW202426451A (zh) * 2022-08-24 2024-07-01 大陸商泰勵生物科技(上海)有限公司 具有抗kras突變腫瘤活性的化合物
WO2024083246A1 (en) * 2022-10-21 2024-04-25 Ascentage Pharma (Suzhou) Co., Ltd. Kras inhibitors
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
CN118165011A (zh) * 2022-12-08 2024-06-11 润佳(上海)医药工程有限公司 Kras抑制剂及其用途
TW202430182A (zh) * 2022-12-14 2024-08-01 大陸商上海科州藥物研發有限公司 作為kras抑制劑的雜環化合物,及其製備和治療用途
US20260207615A1 (en) * 2022-12-23 2026-07-23 Frontier Medicines Corporation Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof
CR20250413A (es) * 2023-04-05 2025-11-06 Pfizer Compuestos de pirido[4,3–d]pirimidina
AU2024272361A1 (en) 2023-05-12 2025-12-18 Jazz Pharmaceuticals Ireland Ltd. Pyrazolo[4,3-f]quinazoline derivatives as modulators of g12d mutant kras useful for the treatment of cancer
CN119101070A (zh) * 2023-06-07 2024-12-10 上海璎黎药业有限公司 一种含氮杂环化合物、其药物组合物及应用
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260054710A (ko) 2023-08-17 2026-04-22 트리라인 바이오사이언시스, 인크. 스피로시클릭 디히드로피라노피리미딘 KRas 저해제
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025163494A1 (en) 2024-01-29 2025-08-07 Jazz Pharmaceuticals Ireland Ltd. Condensed azines for the treatment of cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025235740A1 (en) * 2024-05-08 2025-11-13 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026119095A1 (zh) * 2024-12-05 2026-06-11 上海璎黎药业有限公司 一种肼类结构化合物、其药物组合物及应用
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US12655160B2 (en) * 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4204412A4 (en) * 2020-08-26 2024-10-09 InventisBio Co., Ltd. HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN116323624B (zh) * 2020-09-30 2026-07-10 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
US20240034733A1 (en) * 2020-11-03 2024-02-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
CN113999226B (zh) * 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022256459A1 (en) * 2021-06-01 2022-12-08 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Also Published As

Publication number Publication date
KR20240013776A (ko) 2024-01-30
AU2022279653A1 (en) 2023-11-09
US20240279241A1 (en) 2024-08-22
WO2022248885A2 (en) 2022-12-01
CA3216294A1 (en) 2022-12-01
WO2022248885A3 (en) 2023-02-16
JP2024519170A (ja) 2024-05-08
EP4347589A2 (en) 2024-04-10
MX2023014138A (es) 2024-02-13
IL308438A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
BR112023025869A2 (pt) Derivados de quinazolina úteis como inibidores de ras
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
MX2025006174A (es) Compuestos
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
ZA202003176B (en) Compounds useful as kinase inhibitors
PH12023500023A1 (en) Cdk2 degraders and uses thereof
CA3173629A1 (en) Braf degraders
MX2023013912A (es) Metodos para inhibir ras.
MX2023008677A (es) Derivados de urolitinas y métodos para su uso.
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
CL2020001719A1 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd (divisional solicitud 202000911)
NI202100018A (es) Moduladores de la expresión de pnpla3
EP4438124A3 (en) Methods for treating testicular and ovarian adrenal rest tumors
EA201890394A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ
NI202000085A (es) Moduladores de la expresión de apol1
BR112022021381A2 (pt) Compostos para o tratamento de sars
CO2025008531A2 (es) Inhibidores de malt1
BR112023000654A2 (pt) Composto de pirazolopirimidina usado como inibidor de atr quinase
BR112022003768A2 (pt) Compostos inibidores de perk
WO2021158635A8 (en) Anti-viral compositions and methods of use
MX2025001068A (es) Derivados arilos tricíclicos, y composiciones y métodos de los mismos
PE20201349A1 (es) Moduladores de la expresion de ezh2
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CO2025016192A2 (es) Moléculas y métodos de uso de estas
MX2022014461A (es) Nuevos abridores de canales de potasio maxi-k para el tratamiento de trastornos asociados con x fragil.